Cito Capital Group LLC acquired a new position in shares of Teladoc Health Inc (NYSE:TDOC) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 8,600 shares of the health services provider’s stock, valued at approximately $571,000.
A number of other hedge funds have also recently bought and sold shares of TDOC. Jennison Associates LLC boosted its holdings in shares of Teladoc Health by 60.6% in the 2nd quarter. Jennison Associates LLC now owns 1,172,135 shares of the health services provider’s stock worth $77,841,000 after purchasing an additional 442,140 shares in the last quarter. Manchester Capital Management LLC acquired a new position in shares of Teladoc Health in the first quarter valued at approximately $75,000. Aperio Group LLC raised its position in shares of Teladoc Health by 28.3% in the second quarter. Aperio Group LLC now owns 7,170 shares of the health services provider’s stock valued at $476,000 after buying an additional 1,582 shares during the last quarter. GAM Holding AG acquired a new position in shares of Teladoc Health in the first quarter valued at approximately $2,243,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Teladoc Health by 5.9% in the second quarter. Charles Schwab Investment Management Inc. now owns 583,858 shares of the health services provider’s stock valued at $38,775,000 after buying an additional 32,535 shares during the last quarter.
Shares of Teladoc Health stock traded down $0.78 during trading hours on Wednesday, hitting $67.92. The company’s stock had a trading volume of 13,681 shares, compared to its average volume of 1,153,703. Teladoc Health Inc has a 1-year low of $42.08 and a 1-year high of $89.05. The business has a fifty day moving average of $63.13 and a 200 day moving average of $61.33. The company has a market capitalization of $4.95 billion, a PE ratio of -47.27 and a beta of 1.36. The company has a quick ratio of 7.56, a current ratio of 7.56 and a debt-to-equity ratio of 0.43.
Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, July 31st. The health services provider reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Teladoc Health had a negative return on equity of 10.64% and a negative net margin of 21.85%. The business had revenue of $130.30 million during the quarter, compared to analyst estimates of $129.54 million. During the same period in the previous year, the company earned ($0.40) EPS. Teladoc Health’s revenue was up 37.8% on a year-over-year basis. On average, sell-side analysts anticipate that Teladoc Health Inc will post -1.56 earnings per share for the current fiscal year.
In other Teladoc Health news, SVP Andrew Turitz sold 9,158 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $62.27, for a total transaction of $570,268.66. Following the sale, the senior vice president now directly owns 6,827 shares of the company’s stock, valued at $425,117.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Peter A. Mcclennen sold 29,412 shares of the stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $69.98, for a total transaction of $2,058,251.76. Following the completion of the sale, the president now directly owns 29,412 shares in the company, valued at approximately $2,058,251.76. The disclosure for this sale can be found here. Insiders sold 115,046 shares of company stock valued at $7,811,011 in the last three months. Company insiders own 3.14% of the company’s stock.
TDOC has been the subject of a number of analyst reports. SunTrust Banks boosted their price objective on shares of Teladoc Health to $80.00 and gave the company a “positive” rating in a research report on Tuesday, August 6th. Svb Leerink reissued an “outperform” rating on shares of Teladoc Health in a research report on Thursday, August 1st. Deutsche Bank started coverage on shares of Teladoc Health in a research report on Thursday, September 12th. They issued a “buy” rating and a $76.00 price objective for the company. Piper Jaffray Companies set a $87.00 price target on shares of Teladoc Health and gave the stock a “buy” rating in a research report on Friday, August 16th. Finally, Craig Hallum upped their price target on shares of Teladoc Health from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $82.58.
Teladoc Health Profile
Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Featured Story: What does earnings per share mean?
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health Inc (NYSE:TDOC).
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.